Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Stewart, J.S.W.; E.W. Cohen, Ezra; Licitra, Lisa; M.L. van Herpen, Carla; Khorprasert, Chonlakiet; Soulières, Denis; Vodvářka, P; Rischin, Danny; M. Garin, Avgust; R. Hirsch, Fred; Varella‐Garcia, Marileila; Ghiorghiu, Serban; Hargreaves, Laura; Armour, Alison; Speake, Georgina; Swaisland, Alan; E. Vokes, Everett

doi:10.1200/jco.2008.17.0530

Public

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Published in Journal of Clinical Oncology • Mar 17, 2009

Authors:

J.S.W. Stewart

Ezra E.W. Cohen

Lisa Licitra

Abstract

PURPOSE: To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or standard methotrexate. PATIENTS AND METHODS: Four hundred eighty-six patients with recurrent SCCHN were randomly assigned to oral gef...

Subject

Gefitinib

Medicine

Methotrexate

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!